Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-Term Daidzein Intervention in MASLD
NCT07623044Phase 2Not yet recruiting
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Start
- May 2026
- Primary completion
- Jul 2026
01
Overview
A Phase 2 trial of daidzein in metabolic dysfunction-associated steatotic liver disease (MASLD), sponsored by Eastern Hepatobiliary Surgery Hospital. Planned start May 2026; status: not yet recruiting.
02
Drugs
daidzein
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on NCT07623044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07623044.